We are live on ! Find out more
BSX icon

Boston Scientific

671 hedge funds and large institutions have $41.7B invested in Boston Scientific in 2018 Q2 according to their latest regulatory filings, with 96 funds opening new positions, 224 increasing their positions, 226 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $235M | Put options by funds: $136M

71% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 56

22% more capital invested

Capital invested by funds: $34.3B → $41.7B (+$7.42B)

7% more funds holding in top 10

Funds holding in top 10: 1415 (+1)

6% more funds holding

Funds holding: 633671 (+38)

1.39% more ownership

Funds ownership: 91.23%92.63% (+1.4%)

1% less repeat investments, than reductions

Existing positions increased: 224 | Existing positions reduced: 226

Holders
671
Holders Change
+38
Holders Change %
+6%
% of All Funds
15.36%
Holding in Top 10
15
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.14%
% of All Funds
0.34%
New
96
Increased
224
Reduced
226
Closed
56
Calls
$235M
Puts
$136M
Net Calls
+$98.2M
Net Calls Change
+$86.1M
Name Holding Trade Value Shares
Change
Change in
Stake
SOMRS
151
State of Michigan Retirement System
Michigan
$13.4M +$112K +3,700 +0.9%
DZ Bank
152
DZ Bank
Germany
$13.3M +$3.84M +127,400 +46%
MIM
153
MetLife Investment Management
New Jersey
$13.3M -$229K -7,580 -2%
PWP
154
Private Wealth Partners
California
$13.1M -$82.4K -2,733 -0.7%
WF
155
Welch & Forbes
Massachusetts
$13M -$32.2K -1,069 -0.3%
QIM
156
Quantitative Investment Management
Virginia
$12.8M +$4.83M +160,100 +69%
FAF
157
Fjarde Ap-fonden
Sweden
$12.6M +$311K +10,325 +3%
SSA
158
Schonfeld Strategic Advisors
New York
$12.5M +$1.61M +53,488 +16%
Comerica Bank
159
Comerica Bank
Texas
$12.2M +$37.9K +1,256 +0.3%
Bank of Nova Scotia
160
Bank of Nova Scotia
Ontario, Canada
$12.2M +$5.94M +197,014 +113%
CWG
161
C WorldWide Group
Denmark
$12M
RPAM
162
Rhenman & Partners Asset Management
Sweden
$11.4M
APG Asset Management
163
APG Asset Management
Netherlands
$11.4M
Daiwa Securities Group
164
Daiwa Securities Group
Japan
$11.3M -$1.85M -61,199 -15%
GF
165
Gabelli Funds
New York
$11.2M -$1.75M -58,000 -15%
TPSF
166
Texas Permanent School Fund
Texas
$11M -$559K -18,539 -5%
Zurich Cantonal Bank
167
Zurich Cantonal Bank
Switzerland
$10.8M +$44.4K +1,471 +0.4%
WI
168
Wafra Inc
New York
$10.8M
LOAMS
169
Lombard Odier Asset Management (Switzerland)
Switzerland
$10.8M +$9.93M +329,321 New
DekaBank Deutsche Girozentrale
170
DekaBank Deutsche Girozentrale
Germany
$10.7M +$178K +5,891 +2%
SSA
171
South Street Advisors
New York
$10.7M +$9.86M +326,920 New
US Bancorp
172
US Bancorp
Minnesota
$10.7M +$793K +26,299 +9%
Russell Investments Group
173
Russell Investments Group
United Kingdom
$10.6M -$3.67M -121,607 -27%
Nisa Investment Advisors
174
Nisa Investment Advisors
Missouri
$10.5M +$3.75M +124,350 +64%
SC
175
Samlyn Capital
New York
$10.3M +$9.48M +314,260 New

BSX Hedge Fund Activity: Q2 2018 in Review

671 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q2 2018, worth a combined $41.7B — up 22% from $34.3B a quarter earlier.

Buyers outnumbered sellers: 96 funds opened new BSX positions and 56 closed out — a net gain of 40 holders — while 224 added to existing stakes and 226 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $444M. The largest seller was Eaton Vance Management, cutting an estimated $224M.

  • 671 institutional investors held Boston Scientific (BSX) as of Q2 2018, up from 633 in Q1 2018.
  • Funds reported $41.7B of Boston Scientific stock for Q2 2018, up 22% quarter-over-quarter.
  • 96 funds opened new Boston Scientific positions in Q2 2018 and 56 closed out, a net change of +40 holders.
  • The largest Boston Scientific buyer in Q2 2018 was Fidelity Investments, an estimated $444M added.
  • The largest Boston Scientific seller in Q2 2018 was Eaton Vance Management, an estimated $224M sold.

Based on aggregated 13F filings for Q2 2018.